Aducanumab for Alzheimer's is showing encouraging results as Phase 3 trials roll out. See how this new immunotherapy is treating Alzheimer's at Georgetown University.
This year, Biogen Inc. is executing two Phase 3 clinical trials for aducanumab in Alzheimer’s disease.
Continued below video...
Two global, placebo-controlled studies named ENGAGE and EMERGE are designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease (AD).
“Since the initial readout of our Phase 1b study, we have accelerated our aducanumab clinical program so that we can more fully characterize and confirm the benefit-risk profile of this investigational treatment for Alzheimer’s disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen. “We continue to work with our colleagues around the world to advance the study of aducanumab.”
Aducanumab (BIIB037) is an investigational compound being developed for the treatment of AD. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Aducanumab is thought to target aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of AD patients. Based on pre-clinical and interim Phase 1b data, treatment with aducanumab has been shown to reduce amyloid plaque levels.
RELATED VIDEO + ARTICLE:
Biogen Exceeds Expectations, Helps Clear Alzheimer's Plaque
- Georgetown University